545445-40-7

Basic information

• Product Name: 3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one
• Synonyms: 3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one;5,6-Dihydro-3-(4-morpholinyl)-2(1H)-pyridinone;3-Morpholino-5,6-dihydropyridin-2(1H)-one;5-morpholin-4-yl-2,3-dihydro-1H-pyridin-6-one
• CAS NO: 545445-40-7
• Molecular Formula: C₉H₁₄N₂O₂
• Molecular Weight: 182
• Mol File: 545445-40-7.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 432.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.195
• Storage Temp.: 2-8°C
• PKA: 14.66±0.40(Predicted)
• CAS DataBase Reference: 3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one(545445-40-7)
• EPA Substance Registry System: 3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one(545445-40-7)

Safety Data

• Hazardous Substances Data: 545445-40-7(Hazardous Substances Data)

Usage

General Description

3-Morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one, also known as morantel, is a chemical compound commonly used as an anthelmintic agent in veterinary medicine to treat parasitic infections in livestock. Its molecular structure consists of a morpholine ring and a pyridin-2-one ring, making it a heterocyclic compound. Morantel works by interfering with the neurotransmission in the parasite's muscle cells, ultimately leading to paralysis and expulsion of the parasites from the host organism. It is known for its broad-spectrum activity against various internal parasites, including roundworms, hookworms, and certain species of flukes. Additionally, its low toxicity and minimal adverse effects make it a valuable therapeutic option for the treatment of parasitic infestations in animals.

InChI:InChI=1S/C9H14N2O2/c12-9-8(2-1-3-10-9)11-4-6-13-7-5-11/h2H,1,3-7H2,(H,10,12)

Upstream product

• 1192-28-5 Cyclopentanone oxime 
• 41419-12-9 3,3-dichloro-piperidin-2-one 
• 675-20-7 piperidin-2-one 
• 110-91-8 morpholine 
• 207976-92-9 3-chloro-5,6-dihydro-1H-pyridin-2-one 

Downstream Products

• 1423803-24-0 6-(4-aminophenyl)-1-(4-methoxyphenyl)-(4-methoxyphenyl)-7-carbonyl-1H-pyrazolo[3,4-c]-4,5,6,7-tetrahydropyridine-3-amide 
• 1437577-94-0 6-(4-(5-bromopentanamido)phenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide 
• 1449510-64-8 6-(4-(5-chloropentanamido)phenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide 
• 536759-91-8 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo- 1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester 
• 545445-44-1 5,6?dihydro?3?(4?morpholinyl)?1?[4?(2?oxo?1?piperidinyl)phenyl]?2(1H)?pyridone 

Relevant articles and documents

Pyrazolo [3, 4 - c] pyridine - 7 - ketone compound and use thereof

Belonging to the technical field of medicine, the invention relates to a 4, 5-dihydro-1H-pyrazolo[3, 4-c]pyridine-7-one containing derivative shown as general formula I, and pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein the substituents A, R1 and R2 have meanings given in the specification. The preparation also relates to a preparation method of the general formula I compound and its pharmaceutically acceptable salt or prodrug, medicinal compositions containing the compound and application of the compound as an Xa factor inhibitor, especially application in preparation of drugs for treatment and/or prevention of thromboembolic diseases. (formula I).

A morpholine-free process amenable convergent synthesis of apixaban: a potent factor Xa inhibitor

A convergent synthesis of the anti-coagulant drug apixaban has been efficiently demonstrated on a multi-gram scale. The synthetic route is noteworthy for its brevity and fact that it completely avoids the use of morpholine, a toxic and flammable reagent, in constructing the 5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one core present in apixaban. Graphical abstract: [Figure not available: see fulltext.].

Containing a lactam substituent pyrazole piperidine ketone compound, and its composition and use thereof

The present invention relates to a pyrazolo piperidone compound and a pharmaceutically acceptable composition thereof and use thereof in preparation of medicines for treating Xa-factor associated diseases, and particularly relates to a novel lactam substituent-containing pyrazolo piperidone compound and a pharmaceutical composition containing the compound and use of the compound in preparation of the medicines for the treating Xa-factor associated diseases.